Table 3 Relationships between expression of VEGFR-2,DGFR-β, and c-MET and prognosis in HCC patients who took sorafenib
From: Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
N | PFS OS | ||||||
|---|---|---|---|---|---|---|---|
Months | χ 2 | P | months | χ 2 | P | ||
PDGFR-β | 65 | ||||||
High | 13 | 4.23 | 5.87 | ||||
Low | 52 | 5.60 | 1.345 | 0.246 | 8.97 | 3.996 | 0.046 |
VEGFR-2 | 65 | ||||||
High | 58 | 4.97 | 7.40 | ||||
Low | 7 | 7.93 | 0.391 | 0.532 | 11.37 | 0.514 | 0.473 |
c-MET | 65 | ||||||
High | 55 | 5.60 | 8.97 | ||||
Low | 10 | 1.43 | 6.558 | 0.010 | 6.47 | 0.930 | 0.335 |